HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease
Jul-23-2026

Zydus Lifesciences has received permission to conduct a Phase III clinical trial of Desidustat for patients with sickle cell disease. Conducted in collaboration with the Indian Council of Medical Research (ICMR), the 203-day study will evaluate the efficacy and safety of Desidustat oral tablets in treating anemia. The trial will enrol 164 patients diagnosed with the disease.

The company and ICMR had successfully completed the Phase II Proof-of-concept (PoC) trial to evaluate the efficacy and safety of Desidustat oral tablet for treatment of sickle cell disease. The study met its primary endpoint, demonstrating positive outcomes in line with the trial objectives. The Phase III trial will be a double blind, randomised, placebo controlled, parallel, multicentre, study to evaluate the efficacy and safety of Desidustat oral tablets for treatment of anaemia in sickle cell disease patients.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.


  RELATED NEWS >>